Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LT-1002
- Development stage
- Unknown
- Lead developer
- LTT Bio-Pharma
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Inhalation
01
Overview
LT-1002 is a nebulized formulation of lecithinized superoxide dismutase (PC-SOD) being developed by LTT Bio-Pharma in collaboration with Chong Kun Dang (CKD). PC-SOD is a modified version of the antioxidant enzyme superoxide dismutase, where lecithin is covalently attached to improve tissue affinity and plasma stability. Administered via inhalation using a nebulizer, LT-1002 is designed to deliver the therapeutic enzyme directly to the lungs to scavenge reactive oxygen species (ROS), specifically superoxide radicals. This mechanism aims to reduce oxidative stress and inflammation, which are central to the pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD). The drug is currently in Phase 2 clinical development for these respiratory indications.
- Other names
- Lecithinized Superoxide Dismutase NebulizerPC-SOD NE [Nebulizer]PC-SOD
Beyond the preview
Go deeper on LT-1002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LT-1002.